Menumenu
  • Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck.Abstract

    BACKGROUND: Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. METHODS: The precancer prevalence and incidence rates of 8 comorbid conditions were estimted among a population-based cohort of 1499 patients with SCCHN in the Netherlands

    Landis SH, El-Hariry IA, van Herk-Sukel MP, van den Haak P, Janssen-Heijnen ML, Penning-van Beest FJ, Herings RM. Head Neck. 2012 Feb; 34 (2): 238-44.
  • Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.Abstract

    OBJECTIVE: Numerous studies have suggested a decreased risk of cancer in patients with diabetes on metformin. Because different comparison groups were used, the effect magnitude is difficult to estimate. Therefore, the objective of this study was tfurther analyze whether, and to what extent, use of metformin is associated with a decreased risk of cancer in a cohort of incident users of metformin compared with users of sulfonylurea derivatives

    Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Diabetes Care. 2012 Jan; 35 (1): 119-24.
  • Record linkage for pharmacoepidemiological studies in cancer patients.Abstract

    BACKGROUND: An increasing need has developed for the post-approval surveillance of (new) anti-cancer drugs by means of pharmacoepidemiology and outcomes research in the area of oncology. OBJECTIVES: To create an overview that makes researchers awarof the available database linkages in Northern America and Europe which facilitate pharmacoepidemiology and outcomes research in cancer patients

    van Herk-Sukel MP, Lemmens VE, Poll-Franse LV, Herings RM, Coebergh JW. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 (1): 94-103.
  • Cardiovascular comorbidities among patients with metastatic colorectal cancer.Abstract

    Aim: As comorbidities may impact treatment decisions, prognoses and quality of care, this study determined the rate of comorbid cardiovascular diseases in patients with metastatic colorectal cancer (mCRC). Methods: From the PHARMO Record Linkage Sytem in The Netherlands, all patients with a hospital discharge code for CRC and distant metastasis from 2000-2008 were selected

    Overbeek JA, Zhao Z, van Herk-Sukel MP, Barber BL, Herings R. Journal of Cancer Therapeutics & Research. 2012 online.
  • Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.Abstract

    AIMS/HYPOTHESIS: Several publications suggest an association between certain types of insulin and cancer, but with conflicting results. We investigated whether insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is associated with an increased rik of cancer in a large population-based cohort study

    Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Diabetologia. 2012 Jan; 55 (1): 51-62.
  • Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis.Abstract

    Background. Data is limited on the burden of common comorbidities, such as cardiovascular disease (CVD), respiratory disease and diabetes, or comorbidities related to cancer and its treatment, such as anemia and depression, in patients with soft tisue sarcoma (STS). Patients and Methods. From the Dutch Pathology Registry linked to the PHARMO database (including data on drug use and hospitalizations), 533 patients with STS were selected during 2000-2007 and matched 1 : 10 to cancer-free controls

    van Herk-Sukel MP, Shantakumar S, Overbeek LI, van Boven H, Penning-van Beest FJ, Herings RM. Sarcoma. 2012 2012 402109.
  • Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study.Abstract

    We studied the occurrence of myocardial infarction (MI), ischaemic stroke (IS) and pulmonary embolism (PE) before and after breast cancer hospitalisation compared with cancer-free controls. For this, women with a first breast cancer hospitalisationduring 2000-2007 were selected from the PHARMO Record Linkage System, including drug use and hospitalisations of three million inhabitants in the Netherlands, and matched 1:10 by age to cancer-free women

    van Herk-Sukel MP, Shantakumar S, Kamphuisen PW, Penning-van Beest FJ, Herings RM. Thromb Haemost. 2011 Jul; 106 (1): 149-55.
  • Costs of hospital events in patients with metastatic colorectal cancer.Abstract

    BACKGROUND: In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known sfety profiles with toxicities that may require hospitalizations

    Overbeek JA, Zhao Z, van Herk-Sukel MP, Barber BL, Gao S, Herings RM. J Med Econ. 2011 14 (5): 656-61.
  • The risk for breast cancer is not evidently increased in women with hyperprolactinemia.Abstract

    The question has been raised whether hyperprolactinemia in humans is associated with an excess risk for breast cancer. We aimed to assess the risk of breast cancer in a previously defined large cohort of patients treated for idiopathic hyperprolactnemia or prolactinomas. Based on the pattern of drug prescriptions we identified 11,314 subjects in the PHARMO network with at least one dispensing of dopamine agonists between 1996 and 2006

    Dekkers OM, Romijn JA, deBoer A, Vanden broucke JP. Pituitary. 2010 Sep; 13 (3): 195-8.
  • Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.Abstract

    Observational studies on long-term endocrine treatment among breast cancer patients have presented discontinuation rates on tamoxifen, but lack information on the continuance of any endocrine treatment [both tamoxifen and aromatase inhibitors (AIs)within the same cohort. In this study we determined switching rates from tamoxifen to AIs, discontinuation rates of tamoxifen only, discontinuation rates of any endocrine treatment and determinants of first treatment switch and treatment discontinuation

    van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Breast Cancer Res Treat. 2010 Aug; 122 (3): 843-51.